Trial Profile

Expanded Access to Inhaled Molgramostim Nebulizer Solution in Adults with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Molgramostim (Primary)
Indications Pulmonary alveolar proteinosis
Focus Expanded access; Therapeutic Use
Sponsors Savara Pharmaceuticals

Most Recent Events

03 Oct 2024 Status changed from suspended to recruiting.
27 Sep 2024 According to a Savara Pharmaceuticals media release, The Savara Early Access Program has been reviewed and allowed to proceed by the U.S. Food and Drug Administration (FDA), and it is currently accepting requests from eligible patients in select countries in North America and Europe with plans to expand through 2026.
16 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com